Browse CYB5R2

Summary
SymbolCYB5R2
Namecytochrome b5 reductase 2
Aliases B5R.2; cytochrome b5 reductase b5R.2; NADH-cytochrome b5 reductase 2
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00970 Oxidoreductase FAD-binding domain
PF00175 Oxidoreductase NAD-binding domain
Function

NADH-cytochrome b5 reductases are involved in desaturation and elongation of fatty acids, cholesterol biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin reduction (By similarity). Responsible for NADH-dependent lucigenin chemiluminescence in spermatozoa by reducing both lucigenin and 2-[4-iodophenyl]-3-[4-nitrophenyl]-5-[2,4-disulfophenyl]-2H tetrazolium monosodium salt (WST-1).

> Gene Ontology
 
Biological Process GO:0006694 steroid biosynthetic process
GO:0006820 anion transport
GO:0008202 steroid metabolic process
GO:0015701 bicarbonate transport
GO:0015711 organic anion transport
GO:0016125 sterol metabolic process
GO:0016126 sterol biosynthetic process
GO:1901615 organic hydroxy compound metabolic process
GO:1901617 organic hydroxy compound biosynthetic process
Molecular Function GO:0004128 cytochrome-b5 reductase activity, acting on NAD(P)H
GO:0016651 oxidoreductase activity, acting on NAD(P)H
GO:0016653 oxidoreductase activity, acting on NAD(P)H, heme protein as acceptor
GO:0048037 cofactor binding
GO:0050660 flavin adenine dinucleotide binding
GO:0050662 coenzyme binding
GO:0071949 FAD binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00520 Amino sugar and nucleotide sugar metabolism
Reactome R-HSA-1237044: Erythrocytes take up carbon dioxide and release oxygen
R-HSA-1430728: Metabolism
R-HSA-1480926: O2/CO2 exchange in erythrocytes
Summary
SymbolCYB5R2
Namecytochrome b5 reductase 2
Aliases B5R.2; cytochrome b5 reductase b5R.2; NADH-cytochrome b5 reductase 2
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CYB5R2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCYB5R2
Namecytochrome b5 reductase 2
Aliases B5R.2; cytochrome b5 reductase b5R.2; NADH-cytochrome b5 reductase 2
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CYB5R2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -1.57; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCYB5R2
Namecytochrome b5 reductase 2
Aliases B5R.2; cytochrome b5 reductase b5R.2; NADH-cytochrome b5 reductase 2
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CYB5R2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4550.536
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.5420.378
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3690.728
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0560.894
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4590.785
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4450.817
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2620.644
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4460.672
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1080.927
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.1210.329
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0310.982
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.110.401
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CYB5R2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCYB5R2
Namecytochrome b5 reductase 2
Aliases B5R.2; cytochrome b5 reductase b5R.2; NADH-cytochrome b5 reductase 2
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CYB5R2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCYB5R2
Namecytochrome b5 reductase 2
Aliases B5R.2; cytochrome b5 reductase b5R.2; NADH-cytochrome b5 reductase 2
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CYB5R2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CYB5R2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCYB5R2
Namecytochrome b5 reductase 2
Aliases B5R.2; cytochrome b5 reductase b5R.2; NADH-cytochrome b5 reductase 2
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CYB5R2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCYB5R2
Namecytochrome b5 reductase 2
Aliases B5R.2; cytochrome b5 reductase b5R.2; NADH-cytochrome b5 reductase 2
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CYB5R2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCYB5R2
Namecytochrome b5 reductase 2
Aliases B5R.2; cytochrome b5 reductase b5R.2; NADH-cytochrome b5 reductase 2
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CYB5R2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCYB5R2
Namecytochrome b5 reductase 2
Aliases B5R.2; cytochrome b5 reductase b5R.2; NADH-cytochrome b5 reductase 2
Chromosomal Location11p15.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CYB5R2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.